Thermo Fisher’s New Customizable TaqMan SARS-CoV-2 Mutation Panel Allows Labs to Choose Which Variants to Track

By LabMedica International staff writers
Posted on 11 Mar 2021

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel, a customizable menu of 22 verified real-time PCR assays for identification of SARS-CoV-2 mutations.

These assays enable surveillance of variants that are causing COVID-19 infections in specific regions globally and allow laboratories to choose which mutations to track. The TaqMan SARS-CoV-2 Mutation Panel is designed to be highly scalable, being able to run a few or hundreds of samples to identify one or many mutations. This provides laboratories with the ability to meet various levels of testing need with real-time PCR instruments they already use. The TaqMan SARS-CoV-2 Mutation Panel provides results in about an hour and is based on gold standard TaqMan SNP genotyping assay technology, which can help to detect and distinguish mutations efficiently.

Illustration

"With an evolving virus, having up to date, reliable and accurate information is critical in fighting back," said Mark Smedley, president of the genetic sciences business of Thermo Fisher Scientific. "With this panel, we're empowering researchers and clinicians by putting another tool in their hands to monitor changes in the virus so they can make informed and effective decisions for overall public health."